L'Oréal faces six class actions over CeraVe cancer risk claims
French cosmetics giant L'Oréal is confronting six class-action lawsuits in the United States over its CeraVe acne treatment products, following allegations that benzoyl peroxide can degrade into benzene—a known human carcinogen—under certain temperature conditions. Independent laboratory findings have sparked renewed debate over product safety and transparency in the skincare industry, with cases now consolidated in New York federal courts.
L'Oréal, the French beauty conglomerate, faces mounting legal pressure in the United States as six class-action lawsuits target its popular skincare brand CeraVe. The litigation centres on allegations that specific acne treatments containing benzoyl peroxide, a widely used active ingredient, may break down into benzene—a chemical classified as a human carcinogen—when exposed to elevated temperatures. The lawsuits accuse the company of failing to warn consumers adequately about potential health risks associated with its products.
Independent laboratory raises benzene contamination concerns
At the heart of the legal proceedings lies a March 2024 report from Valisure, an independent testing laboratory, which found that benzoyl peroxide-based acne products could generate significant benzene levels even at temperatures approximating normal human body heat. According to the laboratory's analysis, tests conducted on various benzoyl peroxide formulations stored between 37°C and 70°C detected notable benzene formation. The report particularly highlighted CeraVe's Acne Foaming Cream Cleanser, which contains 4 per cent benzoyl peroxide, and its Acne Foaming Cream Wash, formulated with 10 per cent, as products of primary concern.
Legal proceedings advance through US courts
The first complaint was filed shortly after the Valisure report reached public attention in March 2024, with additional lawsuits emerging across Hawaii, Louisiana, Missouri, Illinois, and New York. Plaintiffs have argued that consumers were not adequately notified about the potential dangers associated with prolonged use or improper storage of the products. In November 2024, attorneys sought to consolidate all cases in Hawaii for procedural efficiency, but a federal judicial panel rejected that request the following February. By May 2025, all six cases had been transferred to the United States District Court for the Southern District of New York for more detailed examination. As of June 2026, no final rulings have been issued, and litigation remains active.
Consumer concerns and industry transparency demands
The allegations have triggered widespread debate across social media platforms, with many long-time users of benzoyl peroxide-based acne treatments questioning the safety of ingredients they have trusted for years. Consumer advocates have called on manufacturers to provide greater transparency regarding production processes and stability testing under various storage conditions. Health experts, meanwhile, have cautioned that the ongoing court cases do not constitute a final determination of liability or confirmed harm, urging the public to await scientific and judicial conclusions before drawing definitive judgments.
Comments you share on our site are a valuable resource for other users. Please be respectful of different opinions and other users. Avoid using rude, aggressive, derogatory, or discriminatory language.